Blog | HemaCare

HemaCare Leukopaks Support Novel Gene Editing Strategy

May 7, 2019 10:07:00 AM / by Nancy Andon, MSc posted in leukopaks, gene editing, hematopoietic stem cells

0 Comments

In an independent publication [1] researchers at UCLA cited using leukopaks obtained from HemaCare in order to investigate a new gene editing method.

The group is researching strategies to treat genetic blood disorders such as sickle cell anemia. While there has been a great deal of research focused on using CRISPR/Cas9 gene therapy to treat these illnesses [2], current strategies for gene editing in hematopoietic stem cells are inefficient, and thus costly.

Read More

HemaCare Leukopaks Aid T Cell Cryopreservation Study

Apr 30, 2019 10:00:00 AM / by Nancy Andon, MSc posted in leukopaks, cell therapy, cell therapy starting material

0 Comments

An independent publication in Nature: Scientific Reports cites using fresh leukopaks sourced from HemaCare in their T cell cryopreservation study. The authors, who work at the Cell and Gene Therapy Catapult in London, are studying the impact of cooling and thawing rates on cryopreserved human peripheral blood-derived T cells. In order for the emerging cell and gene therapy industry to effectively ship and store cell-based therapies to global markets, it will be necessary to cryopreserve cell therapy starting materials, as well as the final therapeutic products. To retain peak cellular function, and therefore therapeutic efficacy upon patient administration, it is necessary to understand how to optimize the cryopreservation process.

Read More

HIV Cell Therapy in Development

Oct 8, 2018 10:13:00 AM / by Stacy Matthews Branch, DVM, PhD posted in leukopak, leukopaks, HIV, T cells

0 Comments

Combining various treatment approaches is seen as a viable, more powerful means to achieve HIV cure states.

From the time that HIV-related illness and death was first realized in the 1980s until now, efforts to fully understand HIV infection and pathogenesis have been ongoing along with massive research efforts to discover a cure or means to control the spread of the virus. The newest antiviral therapies have made an extraordinary impact on the control of disease progression; however, these do not cure HIV infection and the viral activity returns shortly after antiviral dosing stops. Approaches to achieve HIV immunity are heavily studied, including developing means to provide HIV immunity in T cells and conferring HIV-resistance via gene editing. However, combining various approaches is seen as a viable, more powerful means to achieve HIV control or even a cure.

Read More

Everything You Need to Know About Apheresis

Mar 27, 2017 12:41:11 PM / by Stacy Matthews Branch, DVM, PhD posted in leukopaks, apheresis, Innovation, leukemia

0 Comments

Many people have donated blood in their lifetime. This blood is not only used for transfusions, but to provide blood components to treat a number of diseases and to conduct research geared to develop new diagnostic and treatment strategies. To obtain specific blood components, the technique of apheresis is used. This procedure is the means to separate blood into its various components so that the desired one is removed. Then, the rest of the components are placed back into the donor’s circulation.

Read More

Leukopak Versus Buffy Coat

Feb 27, 2017 8:53:23 AM / by Stacy Matthews Branch, DVM, PhD posted in leukopaks, buffy coat, cell therapy, Dendritic cells, leukapharesis procedures, stem cell research

0 Comments

Leukapheresis is a procedure to separate white bloods cells (including dendritic and progenitor cells) from a blood sample. Products obtained from leukapharesis procedures, leukopaks, are regularly used in the research setting. They are also used for cell therapy process development and clinically for certain treatment procedures for blood disorders. Another way to obtain white blood cells and platelets is to obtain them from the buffy coat.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts